This trial is evaluating whether JNJ-63723283 will improve 3 primary outcomes and 19 secondary outcomes in patients with Cancer. Measurement will happen over the course of Up to 2 years and 5 months.
This trial requires 250 total participants across 2 different treatment groups
This trial involves 2 different treatments. JNJ-63723283 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Cancers are usually curable only when they have begun to spread to other parts of the body; curing cancer entails removing the existing cancer from the body. Thus, there are few ways to cure cancer. A cancer can be cured only when all the cells that have developed a tumor are removed. In rare cases cancer can be completely cured with surgery, radiation, chemotherapy and targeted therapy. To date there is insufficient evidence to recommend any strategy (with or without treatment) or cure. Current research in this area is limited.
The cause of cancer remains elusive despite the availability of a large body of evidence for and against several proposed causes. We suspect that the vast majority of cancers are caused by a complex interaction between genetic predisposition and environmental factors, which, we argue, explains the high background incidence of cancer across the human population. These predisposing factors can be measured and/or simulated within the lab to produce cancers that mimic natural disease that cause or are caused by the natural disease.
Surgical interventions such as biopsy, blood tests, and x-rays may indicate an underlying cancer, and the presence of one or combined signs of cancer indicate a greater likelihood of cancer.
In both the current and historical periods, physicians have treated cancer using a variety of methods. Recent discoveries or advances often result in changes to the standard therapy.
About 17 million Americans will develop cancer in 2008, with nearly 70% of cancer diagnoses occurring after age 75. At the same time, the prevalence of diabetes, at 6.7 million children per year and obesity, at 6.8 million children per year, show the growing burden on public health. These diseases will have increased impacts on American society as a whole, as well as on the economy, as they have the potential to curtail productive years.
Most cancer cases are due to the initiation and growth of uncontrolled cell divisions resulting in the formation of cancer. The incidence of cancer is increasing with a global increase in age, lifestyle, and diet. Some of these risk factors are the result of environmental and medical exposure to ionizing radiation, tobacco, drug abuse, alcohol, or other chemicals. Smoking in particular gives a more rapid onset of carcinogenesis than other known carcinogens, and some people are more susceptible to lung cancer from tobacco smoke than others. People who use cannabis are 50% less likely to develop cancer of the urinary bladder than those who do not use it.
These data show beneficial effects of JNJ-63723283 on a variety of measures of QOL, with improvements as early as 12 weeks and maintained over time. These data support the use of cancer chemotherapy under treatment conditions that are compatible with JNJ-63723283.
Currently the therapeutic use of jnj-63723283 and its derivatives in humans and animal models has produced dramatic results. In future the drug promises to be a more effective and less toxic therapy for cancers.
Jnj-63723283 was well tolerated in both Phase 1 studies. The Phase 2 results in one study are consistent with the expected safety/efficacy relationship of a targeted therapy.
Recent findings suggest that the J-Wnt antagonist Jnj-63723283 shows strong anticancer activity that requires active Wnt signaling to achieve. Further studies are warranted to investigate the activity and utility of Jnj-63723283 as a treatment and/or diagnostic tool for a variety of malignancies.
Results should be compared with national and international databases (e.g., Surveillance, Epidemiology, and End Results); results should be compared with other cancer prevention and screening programs; and results should be compared with the cost/benefit of screening the whole population.
In most cases, Jnj-63723283 was not effective for treating specific cancer types or cancer types in specific organs. However, because many patients with cancer suffer from severe pain and other debilitating symptoms, the role of jnj-63723283 and its effects against pain and other debilitating symptoms could not be easily and certainly concluded in many cases. Further studies on the use of jnj-63723283 for treating cancer patients are necessary.